company
Ajinomoto Group
IR
Event
Business Briefing / IR Day

Business Briefing / IR Day

日本語

Back to IR Top

Business Briefing / IR Day

Ajinomoto Group holds business briefings and IR Day for institutional investors and analysts to deepen their understanding of the Group.

FY2025

Medical Food Business Briefing (June 26, 2025)

Opening Remarks （571KB）
Strategy for Our Medical Food Business （1,588KB）
Ajinomoto Cambrooke, Inc. Presentation （5,114KB）
Nualtra Ltd. Presentation （5,429KB）
Glossary （95KB）
Video (Webinar)

IR Day (April 4, 2025)

An Opportunity for Dialogue between Investors and Directors （706KB）
Video Streaming(Webinar)

FY2024

Forge Biologics, Online Information Session (October 1, 2024)

Opening Remarks （1,727KB）
Forge Biologics, Online Information Session (Presentation) （2,465KB）
Video Streaming (Webinar)
Video (What is gene therapy?)
Video (Manufacturing process / Site tour)

Business Briefing (July 1, 2024)

Opening Remarks （812KB）
Marketing Initiatives and the Evolution of Marketing to Realize Enhancement of Corporate Value （3,843KB）
DX Initiatives and the Evolution of DX to Support the Transformation of the Ajinomoto Group （1,972KB）
Video Streaming(Webinar)

FY2023

IR Day (March 27, 2024)

Opening Remarks （1,573KB）
Sustainability Initiatives Aimed at Enhancement of Corporate Value （2,978KB）
Video Streaming(Webinar)

Business Briefing (December 4, 2023)

Opening Remarks （434KB）
Follow-up to the Acquisition of US-Based Forge Biologics Holdings （2,006KB）
Food & Wellness Growth Strategy （2,324KB）
Realizing the Roadmap in Green Area （1,482KB）
Video Streaming Part 1 (Follow-up to the Acquisition of Forge Biologics)
Video Streaming Part 2 (Food & Wellness / Green)

Briefing Session on Acquisition of Forge Biologics, a US-Based Gene Therapy CDMO (November 13, 2023)

Acquisition of the US Based Forge Biologics Holdings （2,300KB）
Video Streaming(Webinar)

IR Day (September 4, 2023)

Business Briefing (June 13, 2023)

Opening Remarks -The Growth Strategy in Our Medium-Term ASV Initiatives- （748KB）
Continuous Growth in Healthcare and ICT through "AminoScience" （3,458KB）
ABF-Based Growth Strategy in ICT （6,524KB）
Growth Strategy for the Biopharmaceutical and Regenerative Medicine Culture Media Business （1,636KB）
Growth Strategy for the Bio-Pharma Services Business （3,243KB）
Video Streaming(Webinar)

FY2022

IR Day (September 14, 2022)

Opening Remarks ー Evolution of ASV Management: Sustainability and Human Assets ー （1,458KB）
Enhancement of Corporate Value through Initiatives Regarding Human Assets （2,704KB）
Video Streaming (Webinar)

Business Briefing (August 25, 2022)

Evolution of ASV Management in the New Executive Team （420KB）
Growth Strategy through Business Model Transformation (BMX) （1,061KB）
Growth Strategy Based on Integration of Food and AminoScience （1,923KB）
Growth Strategy for the Bio-Pharma Services Business （1,771KB）
Video Streaming (Webinar)

FY2021

IR Day (September 29, 2021)

Opening Remarks, The purpose of the change in the form of corporate organization （1,127KB）
Regarding the Board of Directors （1,206KB）
Audit Committee, The Workings of Highly Effective Internal Control （601KB）
Sustainability Initiatives （3,665KB）
Presentation (video)
Q&A session (video)

Virtual Business Briefing & Factory Tour -Functional Materials Business- (June 3, 2021)

Virtual Business Briefing & Factory Tour; Functional Materials Business （3,321KB）
Video Streaming (Webinar)

FY2019

Material for Analyst’s Meeting held on June 12, 2019

Electronic Materials Business Briefing （2,103KB）
Q&A at Analyst's Meeting (June 12, 2019)

FY2018

The 5th Briefing on Integrated Report Topics ~Initiatives for Achieving ASV's Target of “Health and Well-being”

Briefing on Integrated Report Topics ~Initiatives for Achieving ASV's Target of “Health and Well-being” （5,801KB）

Site	Meeting Room, Ajinomoto Co.,Inc.

Time	11：00-13：00, 29 March 2019

Participants	34

The 4th Briefing on Integrated Report Topics ~Generating social value and economic value through R&D (for analysts and institutional investors)

Briefing on Integrated Report Topics ~Generating social value and economic value through R&D （2,981KB）

Site	Client Innovation Center (at Kawasaki Plant)

Time	14：00-16：00, 10 April 2018

Participants	38

FY2017

Material for Analyst’s Meeting held on June 8, 2017

Ajinomoto’s Pharma-related Business employing Leading-Edge Bioscience and Fine Chemical Technologies （2,319KB）

FY2016

ESG Initiatives – Third Briefing: Contributing to Healthy Living through Food and Amino Acids(for analysts and institutional investors)

Briefing on Various ESG-related Initiatives -Contributing to Healthy Living through Food and Amino Acids- （2,793KB）

Site	Ajinomoto National Training Center

Time	10：00-14：00, 27 March 2017

Participants	50

FY2015

ESG Initiatives – Second Briefing: Umami and MSG (for analysts and institutional investors)

Briefing on Various ESG-related Initiatives -“Umami” and MSG- （5,078KB）

Site	Meeting Room, Ajinomoto Co., Inc.

Time	16：00-17：00, 24 March 2016

Participants	52

Material for Analyst’s Meeting held on October 15, 2015

Analyst’s Meeting for AGREEMENT CONCERNING THE INTEGRATION OF THE GASTROINTESTINAL DISEASE BUSINESS OF EISAI CO., LTD. AND AJINOMOTO PHARMACEUTICALS CO., LTD. BY ABSORPTION-TYPE SPLIT （629KB）

FY2014

ESG Initiatives – First Briefing (for analysts and institutional investors)

Site	Meeting Room, Ajinomoto Co., Inc.

Time	15：00-17：00, 27 March 2015

Participants	35

Material for Analyst's Meeting held on February 27, 2015

Analyst’s Meeting for Ajinomoto Co., Inc. to Acquire All Shares of Ajinomoto General Foods, Inc. Held by Mondelēz for JPY 27.0 Billion （1,941KB）

Q&A at Analyst's Meeting (Mar. 2, 2015)

Materials for Analyst's Meeting held on September 10, 2014

Analyst’s Meeting for Ajinomoto Group to Acquire Windsor Quality Holdings, LP, the No. 1 Manufacturer of Asian/Ethnic Frozen Foods in the U.S., for Approximately USD 800 Million （2,498KB）

Q&A at Analyst's Meeting (Sep. 11, 2014)

FY2012

Materials for Analyst's Meeting held on December 25-26, 2012

Analyst’s Meeting for Joint Venture Agreement between Ajinomoto Pharmaceuticals Co., Ltd. and Yoshindo Inc. （115KB）